We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+18.11%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.92B
AUM Growth
+$563M
Cap. Flow
+$657M
Cap. Flow %
13.36%
Top 10 Hldgs %
40.18%
Holding
111
New
29
Increased
28
Reduced
20
Closed
14

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$126M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$95.6M
3
AXSM icon
Axsome Therapeutics
AXSM
+$76.9M
4
BIO icon
Bio-Rad Laboratories Class A
BIO
+$72.2M
5
PRTA icon
Prothena Corp
PRTA
+$62.2M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$186M
2
JNJ icon
Johnson & Johnson
JNJ
+$160M
3
MCK icon
McKesson
MCK
+$127M
4
UNH icon
UnitedHealth
UNH
+$124M
5
ABBV icon
AbbVie
ABBV
+$116M

Sector Composition

Rank Sector Weight
1 Healthcare 90.36%
2 Financials 0.49%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTLT
26
DELISTED
CATALENT, INC.
CTLT
$68M 1.38%
940,000
-15,000
-2% -$1.49M
ITCI
27
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$65.3M 1.33%
1,402,500
+626,996
+81% +$32.8M
SGEN
28
DELISTED
Seagen Inc. Common Stock
SGEN
$61M 1.24%
445,500
-104,500
-19% -$17M
BIO icon
29
Bio-Rad Laboratories Class A
BIO
$8.47B
$60.4M 1.23%
+144,800
New +$72.2M
ALNY icon
30
Alnylam Pharmaceuticals
ALNY
$37.2B
$57.7M 1.17%
+288,500
New +$55M
APLS
31
DELISTED
Apellis Pharmaceuticals
APLS
$57.6M 1.17%
844,000
+629,000
+293% +$37.2M
NTLA icon
32
Intellia Therapeutics
NTLA
$1.49B
$55.9M 1.14%
999,100
-126,094
-11% -$7.82M
IDYA icon
33
IDEAYA Biosciences
IDYA
$3.54B
$55.4M 1.13%
3,715,400
+742,453
+25% +$9.64M
KZR
34
DELISTED
Kezar Life Sciences
KZR
$46.6M 0.95%
541,440
+136,440
+34% +$13.3M
BLU
35
DELISTED
BELLUS Health Inc.
BLU
$45.9M 0.93%
4,346,700
+81,700
+2% +$868K
RVMD icon
36
Revolution Medicines
RVMD
$40B
$45.8M 0.93%
2,321,200
+996,200
+75% +$21.9M
RNAM
37
DELISTED
Avidity Biosciences
RNAM
$42.5M 0.86%
2,600,000
+519,800
+25% +$9.94M
JAZZ icon
38
Jazz Pharmaceuticals
JAZZ
$16B
$42.4M 0.86%
318,300
+256,300
+413% +$39M
ZLAB icon
39
Zai Lab
ZLAB
$2.1B
$42.2M 0.86%
+1,234,000
New +$52.8M
ARWR icon
40
Arrowhead Research
ARWR
$12B
$41.5M 0.84%
1,255,374
-183,625
-13% -$7.41M
PLRX icon
41
Pliant Therapeutics
PLRX
$66.9M
$41.4M 0.84%
+1,981,100
New +$37.9M
DXCM icon
42
DexCom
DXCM
$28.3B
$37.7M 0.77%
+467,600
New +$39.6M
SYK icon
43
Stryker
SYK
$129B
$37.4M 0.76%
+184,700
New +$38.9M
VERV
44
DELISTED
Verve Therapeutics
VERV
$35.8M 0.73%
+1,042,706
New +$33.3M
ALT icon
45
Altimmune
ALT
$576M
$34.3M 0.7%
2,684,000
-297,000
-10% -$4.39M
CNC icon
46
Centene
CNC
$31.6B
$33.6M 0.68%
+432,400
New +$38.6M
CRBU icon
47
Caribou Biosciences
CRBU
$158M
$33.5M 0.68%
3,172,600
+222,600
+8% +$2.07M
AZN icon
48
AstraZeneca
AZN
$263B
$30.9M 0.63%
281,600
-1,467,900
-84% -$186M
NGM
49
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$23.5M 0.48%
+1,798,100
New +$27.2M
DCPH
50
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$22M 0.45%
1,191,800
-8,200
-0.7% -$129K
1
2
3 4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q3 2022 Portfolio in Review

As of Q3 2022, Avidity Partners Management held 111 positions worth $4.92B, up 13% from $4.36B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Avidity Partners Management deployed $657M of net new capital in Q3 2022, opening 29 new positions and adding to 28 existing holdings. Its largest new stake was Sarepta Therapeutics: 948,200 shares worth $105M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 95% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was AstraZeneca, an estimated $186M trimmed.

  • Avidity Partners Management's largest Q3 2022 buy was Sarepta Therapeutics: 948,200 shares worth $105M.
  • Avidity Partners Management added most to Eli Lilly in Q3 2022, an estimated $126M increase.
  • Avidity Partners Management's biggest Q3 2022 reduction was AstraZeneca, cutting an estimated $186M.
  • Avidity Partners Management fully exited Johnson & Johnson in Q3 2022, selling an estimated $160M.
  • Avidity Partners Management's ten largest holdings make up 40% of its $4.92B portfolio in Q3 2022.
  • Avidity Partners Management opened 29 new positions and closed 14 in Q3 2022.
  • Avidity Partners Management's portfolio value rose 13% quarter-over-quarter to $4.92B.

Based on Avidity Partners Management's 13F filing for Q3 2022, filed 14 Nov 2022.